S&P 500   3,243.98 (-1.56%)
DOW   28,539.49 (-1.55%)
QQQ   218.01 (-2.11%)
AAPL   309.24 (-2.85%)
FB   214.27 (-1.68%)
MSFT   161.95 (-1.87%)
GOOGL   1,423.68 (-2.90%)
AMZN   1,830.50 (-1.67%)
CGC   21.84 (-3.58%)
NVDA   239.05 (-4.56%)
BABA   203.84 (-4.64%)
MU   55.34 (-4.19%)
GE   11.49 (-1.96%)
TSLA   544.07 (-3.67%)
AMD   49.10 (-2.48%)
F   8.84 (-1.78%)
NFLX   343.30 (-2.79%)
BAC   32.81 (-2.18%)
DIS   136.18 (-2.78%)
GILD   63.08 (-0.11%)
S&P 500   3,243.98 (-1.56%)
DOW   28,539.49 (-1.55%)
QQQ   218.01 (-2.11%)
AAPL   309.24 (-2.85%)
FB   214.27 (-1.68%)
MSFT   161.95 (-1.87%)
GOOGL   1,423.68 (-2.90%)
AMZN   1,830.50 (-1.67%)
CGC   21.84 (-3.58%)
NVDA   239.05 (-4.56%)
BABA   203.84 (-4.64%)
MU   55.34 (-4.19%)
GE   11.49 (-1.96%)
TSLA   544.07 (-3.67%)
AMD   49.10 (-2.48%)
F   8.84 (-1.78%)
NFLX   343.30 (-2.79%)
BAC   32.81 (-2.18%)
DIS   136.18 (-2.78%)
GILD   63.08 (-0.11%)
S&P 500   3,243.98 (-1.56%)
DOW   28,539.49 (-1.55%)
QQQ   218.01 (-2.11%)
AAPL   309.24 (-2.85%)
FB   214.27 (-1.68%)
MSFT   161.95 (-1.87%)
GOOGL   1,423.68 (-2.90%)
AMZN   1,830.50 (-1.67%)
CGC   21.84 (-3.58%)
NVDA   239.05 (-4.56%)
BABA   203.84 (-4.64%)
MU   55.34 (-4.19%)
GE   11.49 (-1.96%)
TSLA   544.07 (-3.67%)
AMD   49.10 (-2.48%)
F   8.84 (-1.78%)
NFLX   343.30 (-2.79%)
BAC   32.81 (-2.18%)
DIS   136.18 (-2.78%)
GILD   63.08 (-0.11%)
S&P 500   3,243.98 (-1.56%)
DOW   28,539.49 (-1.55%)
QQQ   218.01 (-2.11%)
AAPL   309.24 (-2.85%)
FB   214.27 (-1.68%)
MSFT   161.95 (-1.87%)
GOOGL   1,423.68 (-2.90%)
AMZN   1,830.50 (-1.67%)
CGC   21.84 (-3.58%)
NVDA   239.05 (-4.56%)
BABA   203.84 (-4.64%)
MU   55.34 (-4.19%)
GE   11.49 (-1.96%)
TSLA   544.07 (-3.67%)
AMD   49.10 (-2.48%)
F   8.84 (-1.78%)
NFLX   343.30 (-2.79%)
BAC   32.81 (-2.18%)
DIS   136.18 (-2.78%)
GILD   63.08 (-0.11%)
Log in

NASDAQ:ORGO - Organogenesis Stock Price, Forecast & News

$4.70
-0.14 (-2.89 %)
(As of 01/27/2020 11:00 AM ET)
Today's Range
$4.70
Now: $4.70
$4.79
50-Day Range
$4.44
MA: $4.92
$5.32
52-Week Range
$3.56
Now: $4.70
$29.65
Volume7,788 shs
Average Volume73,632 shs
Market Capitalization$445.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORGO
CUSIPN/A
CIKN/A
Phone781-575-0775

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$193.45 million
Book Value$0.52 per share

Profitability

Miscellaneous

Employees700
Market Cap$445.28 million
Next Earnings Date3/9/2020 (Confirmed)
OptionableNot Optionable

Receive ORGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.


Organogenesis (NASDAQ:ORGO) Frequently Asked Questions

What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc (NASDAQ:ORGO) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The firm had revenue of $64.27 million for the quarter, compared to analysts' expectations of $64 million. View Organogenesis' Earnings History.

When is Organogenesis' next earnings date?

Organogenesis is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Organogenesis.

How can I listen to Organogenesis' earnings call?

Organogenesis will be holding an earnings conference call on Monday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis updated its fourth quarter 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $72.6-74.6 million, compared to the consensus revenue estimate of $70.41 million.

What price target have analysts set for ORGO?

7 brokerages have issued 12-month price targets for Organogenesis' stock. Their forecasts range from $9.00 to $12.00. On average, they anticipate Organogenesis' share price to reach $10.29 in the next year. This suggests a possible upside of 117.5% from the stock's current price. View Analyst Price Targets for Organogenesis.

What is the consensus analysts' recommendation for Organogenesis?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Organogenesis.

Has Organogenesis been receiving favorable news coverage?

News stories about ORGO stock have been trending somewhat negative on Monday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Organogenesis earned a news impact score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Organogenesis.

Are investors shorting Organogenesis?

Organogenesis saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 76,300 shares, a decrease of 9.7% from the December 31st total of 84,500 shares. Based on an average daily trading volume, of 140,300 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.7% of the shares of the company are short sold. View Organogenesis' Current Options Chain.

Who are some of Organogenesis' key competitors?

What other stocks do shareholders of Organogenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Opko Health (OPK), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Aptinyx (APTX), AzurRx BioPharma (AZRX), OrganiGram (OGI), vTv Therapeutics (VTVT), Main Street Capital (MAIN), Altria Group (MO) and Uber Technologies (UBER).

Who are Organogenesis' key executives?

Organogenesis' management team includes the folowing people:
  • Mr. Gary S. Gillheeney Sr., Pres, CEO & Director (Age 64)
  • Mr. Timothy M. Cunningham, Chief Financial Officer (Age 57)
  • Mr. Patrick Bilbo, Chief Operating Officer (Age 57)
  • Ms. Lori H. Freedman, VP & Gen. Counsel (Age 52)
  • Angelyn Lowe, Director of Corp. Communications

How do I buy shares of Organogenesis?

Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $4.73.

How big of a company is Organogenesis?

Organogenesis has a market capitalization of $448.05 million and generates $193.45 million in revenue each year. Organogenesis employs 700 workers across the globe.View Additional Information About Organogenesis.

What is Organogenesis' official website?

The official website for Organogenesis is http://organogenesis.com/.

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The company can be reached via phone at 781-575-0775 or via email at [email protected]


MarketBeat Community Rating for Organogenesis (NASDAQ ORGO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Organogenesis and other stocks. Vote "Outperform" if you believe ORGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel